Prognostic Stage III Breast Cancer AJCC v8 Completed Phase 2 Trials for Mirvetuximab (DB16235)

Also known as: Prognostic Stage 3 Breast Cancer AJCC v8

IndicationStatusPhase
DBCOND0109635 (Prognostic Stage III Breast Cancer AJCC v8)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03106077Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast CancerTreatment